Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Edwards Lifesciences Corp.

Share:
Related EW
18 Biggest Mid-Day Gainers For Wednesday
Benzinga's Top Upgrades
Medtronic Earnings Face FX Headwinds, But Cardiac Trends Good (Investor's Business Daily)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. (NYSE: EW), and raised its price target from $115.00 to $125.00.

Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.”

Edwards Lifesciences Corp. closed on Thursday at $102.88.

Latest Ratings for EW

DateFirmActionFromTo
Jul 2016JMP SecuritiesMaintainsMarket Outperform
Jul 2016UBSMaintainsBuy
Jul 2016CitigroupMaintainsSell

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!